Plasma aldosterone response to metoclopramide is unmodified by hyperprolactinemia.
It has been previously demonstrated that patients with hyperprolactinemia have impaired PRL response to dopaminergic blockade and increased TSH response. Since inhibitory dopaminergic modulation of aldosterone is well established, we have examined whether prolactinoma patients have an altered aldosterone response to dopaminergic blockade. To investigate this possibility we compared the plasma PRL, TSH and aldosterone responses to the dopamine (DA) antagonist metoclopramide (MCP; 10 mg i.v.) in 10 women with prolactinomas and 7 healthy female controls. Basal PRL levels in prolactinoma patients were elevated and showed a blunted rise following MCP. Although basal TSH levels were similar in the 2 groups of subjects, they significantly increased (p = 0.017) in prolactinoma patients while in contrast they did not significantly change in control subjects. Basal supine plasma aldosterone was similar in patients with prolactinomas (0.23 +/- 0.03 nmol/l) and in healthy subjects (0.25 +/- 0.04 nmol/l) and the increased aldosterone concentrations from 15 to 120 min following MCP were not significantly different in prolactinoma patients and in control subjects. It is concluded that in patients with prolactinomas, the alteration in the dopaminergic regulation is specifically related to the lactotroph.
D000328:Adult; D000450:Aldosterone / Q000097:blood*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000503:physiopathology*; D008787:Metoclopramide / Q000494:pharmacology*; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000503:physiopathology; D011388:Prolactin / Q000097:blood; D013972:Thyrotropin / Q000097:blood
D000450:Aldosterone; D011388:Prolactin; D013972:Thyrotropin; D008787:Metoclopramide